STI-associated syndromes guide: Proctitis

This guide provides an overview of the management and empiric treatment of sexually transmitted infection (STI) - associated proctitis, which is an inflammation of the rectal mucosa, not extending beyond 10–12 cm of the anal verge.

On this page:

Public health importance

Infections of the anus and rectum are often sexually transmitted and are typically associated with receptive anal sex involving direct or indirect contact with rectal mucosal membranesFootnote 1.

Common STI-associated etiology

Proctitis can be a polymicrobial infection. Sexually transmitted infections (STIs) associated with proctitis include Chlamydia trachomatis (CT) (Lymphogranuloma venereum [LGV] and non-LGV genotypes), Neisseria gonorrhoeae (GC), Treponema pallidum and Herpes simplex virus (HSV)Footnote 2.

In one study of gay, bisexual and other men who have sex with men (gbMSM) with proctitis, the following etiological agents were identifiedFootnote 3:

Since most provinces and territories are experiencing syphilis outbreaks, consider syphilis in people presenting with proctitis and anogenital ulcer disease (AUD) or rashes.

In persons with advanced human immunodeficiency virus (HIV) infection, consider cryptosporidium and microsporidium in the differential diagnosisFootnote 2.

Enteric infections can also be acquired through oral-anal sexual activities and result in proctocolitis and enteritisFootnote 2. Proctocolitis may be associated with LGV genotypes of C. trachomatis, Entamoeba histolytica, Campylobacter species, Salmonella species and Shigella species. Enteritis may be associated with Giardia lamblia infection. Consult an experienced colleague for the treatment and management of proctocolitis and enteritis as these are beyond the scope of this guide.

Clinical manifestations

Symptoms and signs of proctitis include:

Suspect LGV if inguinal or femoral lymphadenopathy are present or if there is a history of condomless receptive anal sex and acute hemorrhagic proctitis or proctocolitis. Bloody, purulent or mucous discharge from the anus as well as constipation are common with LGVFootnote 4Footnote 5Footnote 6Footnote 7.

In people with HIV, there are additional potential causes of proctitis and infections are often more severe: acute proctitis may present with bloody discharge, painful perianal ulcers or mucosal ulcersFootnote 8.

Abdominal pain, diarrhoea, cramping, bloating, nausea or fever are often associated with enteric pathogens, which can be transmitted through sexual activity involving fecal-oral contact, and with infections higher in the intestinal tract.

Proctitis may also be secondary to inflammatory bowel disease (IBD)Footnote 9.

Diagnostic testing

Empiric treatment and management

The decision to treat empirically or to wait for test results should reflect the:

When treating empirically, the presence of anorectal exudate is an indication to treat for both GC and CTFootnote 8Footnote 10.

Empiric treatment for proctitis

Ceftriaxone 250 mg IM in a single dose [A-l] or Cefixime 800 mg PO in a single dose [A-l]
plus
Azithromycin 1 g PO in a single dose [B-ll] or Doxycycline 100 mg PO BID for 7-10 days [B-ll]

Notes:

Treat current sexual partners with the same empiric treatment regimen as the index case.

Refer to etiology-specific guides for the treatment of suspected Syphilis or  Genital herpes infections.

Follow-up

Evaluate response to treatment in all individuals treated for proctitis. Consider referring individuals with persistent or recurrent proctitis to an experienced colleague, a gastroenterologist or an infectious disease specialist for further investigation.

The need for test of cure (TOC) depends on which pathogen is confirmed by laboratory testing. Refer to the etiology-specific guide.

Reporting and partner notification

When treatment is indicated for an STI: notify, evaluate, test and treat (as appropriate) sexual partners. Refer to the etiology-specific guide(s) for guidance on reporting and partner notification.

References

Footnote 1

Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2002. MMWR Recomm Rep. 2002;51(RR-6):1-78.

Return to footnote 1 referrer

Footnote 2

Rompalo AM. Diagnosis and treatment of sexually acquired proctitis and proctocolitis: an update. Clin Infect Dis 1999;28(Supplement_1):S84-S90.

Return to footnote 2 referrer

Footnote 3

Albrecht MA, Hirsch MS, McGovern B. Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection. Uptodate http://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-infection 2014:1-68.

Return to footnote 3 referrer

Footnote 4

Nieuwenhuis RF, Ossewaarde JM, Götz HM, et al. Resurgence of lymphogranuloma venereum in Western Europe: an outbreak of Chlamydia trachomatis serovar l2 proctitis in The Netherlands among men who have sex with men. Clin Infect Dis 2004;39(7):996-1003.

Return to footnote 4 referrer

Footnote 5

Kropp RY, Wong T, Canadian LGV Working Group. Emergence of lymphogranuloma venereum in Canada. CMAJ 2005: 172(13):1674-1676.

Return to footnote 5 referrer

Footnote 6

Weir E. Lymphogranuloma venereum in the differential diagnosis of proctitis. CMAJ 2005 Jan 18;172(2):185.

Return to footnote 6 referrer

Footnote 7

Goen JL, Schwartz RA, De Wolf K. Mucocutaneous manifestations of chancroid, lymphogranuloma venereum and granuloma inguinale. Am Fam Physician. 1994;49(2):415-425.

Return to footnote 7 referrer

Footnote 8

Workowski KA, Bolan GA, Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 2015 Jun 5;64(RR-03):1-137.

Return to footnote 8 referrer

Footnote 9

Høie S, Knudsen LS, Gerstoft J. Lymphogranuloma venereum proctitis: a differential diagnose to inflammatory bowel disease. Scand J Gastroenterol 2011;46(4):503-510.

Return to footnote 9 referrer

Footnote 10

Swygard H, Seña AC, Cohen MS. Treatment of uncomplicated Neisseria gonorrhoeae infections. UpToDate 2019.

Return to footnote 10 referrer

Footnote 11

Kong FY, Tabrizi SN, Law M, et al. Azithromycin versus doxycycline for the treatment of genital chlamydia infection: a meta-analysis of randomized controlled trials. Clin Infect Dis. 2014;59(2):193-205

Return to footnote 11 referrer

Footnote 12

Hathorn E, Opie C, Goold P. What is the appropriate treatment for the management of rectal Chlamydia trachomatis in men and women? Sex Transm Infect 2012; 88(5):352-354.

Return to footnote 12 referrer

Footnote 13

Lyss SB, Kamb ML, Peterman TA, et al. Chlamydia trachomatis among patients infected with and treated for Neisseria gonorrhoeae in sexually transmitted disease clinics in the United States. Ann Intern Med 2003; 139(3):178-185.

Return to footnote 13 referrer

Footnote 14

Tapsall JW. What management is there for gonorrhea in the postquinolone era? Sex Transm Dis 2006;33(1):8-10.

Return to footnote 14 referrer

Footnote 15

Workowski KA, Berman S, Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010 Dec 17;59(RR-12):1-110.

Return to footnote 15 referrer

Footnote 16

World Health Organization. Guidelines for the Management of Sexually Transmitted Infections. 2003.

Return to footnote 16 referrer

Page details

Date modified: